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The decision of naive Th cells to assume the fate of effector or regulator Th cells heavily influences the
outcome of adaptive immune responses. In this issue of Immunity, Delgoffe et al. (2009) use genetic
approaches and demonstrate that mTOR kinase plays a critical role in this decision-making process.Naive peripheral CD4+ T helper (Th) cells
have the potential to differentiate into
effector cells, which can be divided into
several functional subsets, including Th1,
Th2, and Th17 cells (Zhu and Paul, 2008).
The differentiation of each effector Th cell
subset is dictated by distinct transcription
factors: STAT4 and T-bet for Th1 cells,
STAT6 and GATA-3 for Th2 cells, and
STAT3 and RORgt for Th17 cells. The func-
tion of effector Th cells is counter-regu-
lated by regulatory T (Treg) cells, which
express Foxp3. Treg cells can come from
two sources. Natural Treg (nTreg) cells
are generated during thymic ontogeny,
whereas induced Treg (iTreg) cells are
differentiated from naive peripheral Th
cells when they are activated in the pres-
ence of TGF-b and IL-2. The balance
between effector Th cells and Treg cells
can critically influence the outcomes of
many human diseases. Although the cyto-
kine milieu and transcription factors that
dictate the differentiation of Th cells have
been well characterized, the Th cell-
intrinsic signaling pathways that regulate
the balance between effector and Treg
cells are still not fully understood. In this
issue of Immunity, Delgoffe et al. (2009)
provide convincing evidence showing
that mTOR (mammalian target of rapamy-
cin) is positioned at the effector-iTreg cell
crossroad, mentoring differentiating Th
cells to become effector Th cells instead of
iTreg cells.
mTOR, a serine and threonine kinase,
is the core component of two protein
complexes: mTORC1 and mTORC2 (Fig-
ure 1; Thomson et al., 2009). mTORC1 is
activated by PI3-kinase sequentially
through Akt and Rheb, a RAS-like GTPase.
mTORC2 is also activated by PI3K but
enhances the phosphorylation of Akt.
mTOR can integrate extracellular stimuli
and participate in many biologicalprocesses, ranging from cell growth
to autophagy. The conventional dogma
is that mTORC1 is sensitive, whereas
mTORC2 is resistant to rapamcyin.Several
recent studies taking advantage of
mTOR’s sensitivity to rapamycin have
discovered that mTOR also plays a critical
role in regulating the development, activa-
tion, and proliferation of Th cells. In addi-
tion, it was found that rapamycin induced
the expression of Foxp3 and promoted the
differentiation of Treg cells (Sauer et al.,
2008). However, these results have never
been confirmed with genetic studies. It
is also unclear whether mTOR impacts
on the differentiation of effector Th cells
and what the unique role of each mTOR
complex is in suppressing the expression
of Foxp3. Unfortunately, germline defi-
ciency of mTOR leads to embryonic death,
prohibiting detailed analysis on the differ-
entiation and function of mTOR-deficient
Th cells. Delgoffe et al. (2009) used the
conventional cre-lox system to delete the
mTOR gene, therefore wiping out both
mTORC1 and mTORC2 only in T cells.
Their results in some aspects are in line
with those deduced from pharmacologi-
cal approaches but also reveal several
surprises.
Rapamycin is a potent inhibitor of proli-
feration of Th cells but only modestly
suppresses the production of IL-2.
Expectedly, mTOR-deficient Th cells
secreted a normal amount of IL-2 when
activated in vitro but proliferated poorly.
Although rapamycin can influence the
differentiation of effector Th cells indi-
rectly through modulating the activity
of antigen-presenting cells (Weichhart
et al., 2008), a Th cell-intrinsic role of
mTOR in regulating the differentiation of
effector Th cells has never been clearly
defined. Delgoffe et al. (2009) showed
that mTOR-deficient Th cells were incom-Immunitypetent in differentiating into effector
Th cells even under optimal conditions.
The defect in differentiating into Th1 cells
was also demonstrated when mice
harboring mTOR-deficient Th cells that
carry a HA-specific T cell recptor trans-
gene were infected with HA-expressing
vaccinia virus. mTOR-deficient Th cells
were unable to upregulate subset-
specific transcription factors, such as
GATA-3, T-bet, and RORgt. They further
demonstrated that the inability to differen-
tiate into effector Th cells was due to
attenuation of respective STAT signals in
response to polarizing cytokines. Instead,
mTOR-deficient Th cells have a tendency
to differentiate into Foxp3-expressing
iTreg cells. When stimulated in vitro with
anti-CD3 alone, there was a marked
increase in the number of Foxp3+ cells,
which also expressed GITR (a member
of the TNF receptor family expressed on
Treg cells) and exhibited Treg cell activity.
Such an increase in the number of Foxp3-
expressing Th cells was also observed
when mTOR-deficient Th cells were acti-
vated in vivo with HA-expressing vaccinia
virus, a setting that is supposed to induce
vigorous Th1 cell responses. Thus, mTOR
in Th cells is required for their differentia-
tion into effector Th cells and for concom-
itantly keeping the expression of Foxp3
in check. The abnormal expansion of
Foxp3-expressing mTOR-deficient Th cells
can be at least partly attributed to de novo
differentiation from naive Th cells. But
a contribution from expansion of nTreg
cells cannot be completely ruled out,
given that rapamycin is relatively inef-
fective in inhibiting the proliferation of
already differentiated Treg cells. mTOR-
deficient Th cells were indeed more sensi-
tive to TGF-b. But deficiency of mTOR
also enhanced the expression of Foxp3
through a TGF-b-independent pathway,30, June 19, 2009 ª2009 Elsevier Inc. 759
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PreviewsFigure 1. A Schematic Diagram of the mTOR Pathway and Its Role in Regulating the
Differentiation of Effector and Induced Regulatory Th Cells
mTOR is the key component of two protein complexes: mTORC1 and mTORC2. mTORC1 is activated by
Akt, whereas mTORC2 enhances the phosphorylation of Akt. mTOR facilitates the differentiation of
effector Th cells by augmenting the strength of respective STAT signal. Reciprocally, mTOR suppresses
the expression of Foxp3 in differentiating Th cells by attenuating TGF-b signaling and also via a TGF-b-
independent mechanism. The negative effect of mTOR on the induction of Foxp3, although sensitive to
rapamycin, can be mediated by mTORC2. But it remains unclear which mTOR complex is responsible
for supporting the differentiation of effector Th cells. In contrast to its role in the differentiation of iTreg cells,
mTOR probably has little influence on the development of nTreg cells.as shown by the fact that in vitro activated
mTOR-deficient Th cells still expressed
an abnormally high Foxp3 even when
TGF-b was blocked. This observation is
in agreement with a previous study
showing that premature termination of
TCR and CD28 costimulation followed
by rapamycin led to a strong induction of
Foxp3 even in the absence of TGF-b
signals (Sauer et al., 2008).
Despite this striking effect of mTOR
deficiency on the induction of Foxp3 in
naive Th cells, the number and frequency
of nTreg cells in mTOR-deficient mice
were normal. It has been shown that over-
expression of a constitutively active Akt
(Akt*) inhibits the development of nTreg
cells and the differentiation of iTreg cells
(Haxhinasto et al., 2008). The effect of
Akt* on iTreg cells can be counteracted
by rapamycin. However, administration
of rapamycin had little impact on the
homeostasis of nTreg cells. This discrep-
ancy suggests that Akt negatively regu-
lates the development of natural, but
not induced, Treg cells by an mTOR-inde-
pendent mechanism. Alternatively, there
might exist a rapamycin-resistant mTOR760 Immunity 30, June 19, 2009 ª2009 Elsepathway that operates in nTreg cells.
Although Delgoffe et al. (2009)’s data are
consistent with the former hypothesis,
their results still leave room for specula-
tion. It is unclear when Akt influences the
expression of Foxp3 during the ontogeny
of nTreg cells. Although the gene that
encodes mTOR was deleted at a late DN
stage, the residual mTOR protein might
be sufficient to mediate the effect of Akt.
This scenario can also explain why the
number of double-positive thymocytes
was not reduced in mTOR-deficient mice,
an unexpected result given that adminis-
tration of rapamycin leads to thymic
atrophy.
The big surprise came when Delgoffe
et al. (2009) tried to determine which
mTOR complex is responsible for sup-
pressing Foxp3 expression. The effect of
mTOR deficiency more or less recapitu-
lates that of rapamycin, so one would
predict that mTORC1, but not the rela-
tively rapamycin-resistant mTORC2, is
the culprit. Unexpectedly, they found that
ablating mTORC1 by deleting Rheb did
not enhance the expression of Foxp3 or
the differentiation of iTreg cells. A straight-vier Inc.forward interpretation of this result is that
mTORC2 alone is sufficient to keep Foxp3
in check. If so, then how do we compro-
mise this result with the observation that
rapamycin enhances the expression of
Foxp3? It has been shown that prolonged
exposure to rapamycin can also affect the
assembly and function of mTORC2 in
some types of cells. For example, treating
Jurkat T cells with rapamycin for 24 hr
nearly completely abrogated the forma-
tion of mTORC2 and strongly attenuated
the phosphorylation of Akt (Sarbassov
et al., 2006), a downstream event of
mTORC2. Thus, the conventional dogma
that rapamycin inhibits only mTORC1 but
not TORC2 is probably inaccurate. This
unexpected finding will have significant
impact on future efforts trying to under-
stand how mTOR regulates the transcrip-
tional program during the differentiation
of iTreg cells.
This study clearly demonstrates that
mTOR critically controls the balance
between effector and iTreg cells. But
several important questions remain unan-
swered. Is mTOR required for preventing
fully differentiated effector Th cells from
redifferentiating into iTreg cells? The
family of Th cells has expanded rapidly
over the past few years. In addition to
the aforementioned Th cell subsets, follic-
ular Th cells, IL-10-producing Tr1 cells,
and IL-9-producing Th cells have been
identified and shown to display distinct
cytokine and transcriptional profiles.
What is the role of mTOR in the differenti-
ation of these subsets of Th cells? mTOR
appears to regulate the differentiation of
Th cells at the level of cytokine signaling.
What is its mechanism of action? Most
intriguingly, what are the unique and
common roles of mTORC1 and mTORC2
in Th cells? Although Delgoffe et al.
(2009)’s paper indicates that mTORC2 is
sufficient to suppress Foxp3 expression,
it is premature to disregard the contribu-
tion from mTORC1. It is still possible that
either mTORC1 or mTORC2 is sufficient
to keep the expression of Foxp3 in check.
Akt activates mainly mTORC1. The obser-
vation that Akt* inhibits the induction of
Foxp3 in naive Th cells in a rapamycin-
sensitive manner would argue strongly
for a role for mTORC1. In addition, the
contribution of mTORC1 and mTROC2
to the control of the proliferation, differen-
tiation, and activation of effector Th cells
has yet to be addressed. Sensitivity to
Immunity
Previewsrapamycin is probably not unique to
mTORC1, so addressing these questions
will have to rely on additional inhibitors or
conditional gene ablation that specifically
interfere with mTORC1 or mTORC2.
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charide; and second, activation of a cas-
pase-1 inflammasome (Figure 1).
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NLRP3-deficient mice have been ge-
nerated and extensively used in the past
few years, and this animal model has
proven invaluable to identify the molecular
structures and the pathogens detected by
this NLR protein. However, Nlrp3/ mice
offer little information with regard to human
pathologies characterized by NLRP3 mu-
tations, because these are gain-of-func-
tion mutations. Two studies, by the groups
of Strober and Hoffman, published in this
issue of Immunity (Meng et al., 2009;
Brydges et al., 2009), now report the
generation of gene-targeted mice carrying
mutations that precisely mimic amino acid
substitutions in NLRP3 found to cause
disease susceptibility in humans. Meng
et al. (2009) generated a mouse strain ex-
pressing a R258W mutation in mouse
Nlrp3 gene, corresponding to the R260W
substitution found in humans. In a slightly
different approach, Brydges et al. (2009)
generated two mouse strains carrying
mutations (A350V and L351P; corre-
sponding to mutations A352V and L353P
in humans) downstream of a LoxP-flanked
neomycin resistance (NeoR) cassette in
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